J&J's (JNJ) Janssen Receives FDA Panel Backing for MDR-TB Drug Bedaquiline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
J&J's (JNJ) Experimental TB Drug Receives Unanimous FDA Panel Backing
November 28, 2012 5:19 PM ESTJohnson & Johnson (NYSE: JNJ) got some good news late Wednesday after an FDA panel said it would back its experimental tuberculosis drug, bedaquiline.
The drug targets adenosine triphosphate synthase, which is an enzyme that TB needs to generate energy.
The... More
